These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21701232)

  • 1. A high proliferative index of recurrent melanoma is associated with worse survival.
    Tu TJ; Ma MW; Monni S; Rose AE; Yee H; Darvishian F; Polsky D; Berman RS; Shapiro RL; Pavlick AC; Mazumdar M; Osman I
    Oncology; 2011; 80(3-4):181-7. PubMed ID: 21701232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
    Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
    [No Abstract]   [Full Text] [Related]  

  • 6. Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients.
    Rosenbaum BE; Schafer CN; Han SW; Osman I; Zhong H; Brinster N
    Mod Pathol; 2017 Oct; 30(10):1402-1410. PubMed ID: 28731044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
    Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
    Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
    Lawrence NF; Hammond MR; Frederick DT; Su Y; Dias-Santagata D; Deng A; Selim MA; Mahalingam M; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2016 Sep; 75(3):595-602. PubMed ID: 27543214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
    Naffouje S; Naffouje R; Bhagwandin S; Salti GI
    Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of initial stage on metastatic melanoma survival.
    Wilson MA; Zhong J; Rosenbaum BE; Utter K; Moran U; Darvishian F; Polsky D; Berman RS; Shapiro RL; Pavlick AC; Osman I
    Melanoma Res; 2019 Jun; 29(3):281-288. PubMed ID: 31026246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics.
    Luen S; Wong SW; Mar V; Kelly JW; McLean C; McArthur GA; Haydon A
    Am J Clin Oncol; 2018 Jan; 41(1):90-94. PubMed ID: 26325493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
    Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
    J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study.
    Liang C; Li D; Liang Y; Xie Y; Lin N; Guan H; Hu W; Guan Y; Liang Y
    Ann Surg Oncol; 2024 Jul; 31(7):4594-4604. PubMed ID: 38689172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.
    Ramsay JA; From L; Iscoe NA; Kahn HJ
    J Invest Dermatol; 1995 Jul; 105(1):22-6. PubMed ID: 7615970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
    Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
    Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and Surgical Outcomes for Pediatric Head and Neck Melanoma.
    Richards MK; Czechowicz J; Goldin AB; Gow KW; Doski J; Goldfarb M; Nuchtern J; Langer M; Beierle EA; Vasudevan S; Gupta D; Parikh SR
    JAMA Otolaryngol Head Neck Surg; 2017 Jan; 143(1):34-40. PubMed ID: 27607058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maspin expression and melanoma progression: a matter of sub-cellular localization.
    Martinoli C; Gandini S; Luise C; Mazzarol G; Confalonieri S; Giuseppe Pelicci P; Testori A; Ferrucci PF
    Mod Pathol; 2014 Mar; 27(3):412-9. PubMed ID: 24030740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.
    Hao M; Zhao G; Du X; Yang Y; Yang J
    Tumour Biol; 2016 Aug; 37(8):10339-48. PubMed ID: 26846098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
    Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
    Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased shedding of HU177 correlates with worse prognosis in primary melanoma.
    Hamilton HK; Rose AE; Christos PJ; Shapiro RL; Berman RS; Mazumdar M; Ma MW; Krich D; Liebes L; Brooks PC; Osman I
    J Transl Med; 2010 Feb; 8():19. PubMed ID: 20178639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.